• Maria Nikolaou, Christina Chrysohoou, Theodosis Anastasios Georgilas, Gregory Giamouzis, George Giannakoulas, Apostolos Karavidas, Christodoulos Papadopoulos, Sotirios Patsilinakos, Dimitrios Tziakas, John Parissis, and Hellenic Iron Consensus Group.
• Cardiology Department, General Hospital "Sismanogleio-Amalia Fleming", Athens, Greece. Electronic address: marianikolaou1974@yahoo.com.
• Eur. J. Intern. Med. 2019 Jul 1; 65: 17-25.

AbstractHeart Failure (HF) is a global pandemic with rapidly increasing prevalence. In an attempt to maintain patients well being, the therapeutic interest has expanded to the vicious cycles that confer to HF mortality and morbidity and a number of comorbidities have been targeted. Iron deficiency represents a common comorbid condition that affects outcomes in HF. The treatment of iron deficiency is strongly supported by the cardiologic societies all over the world. Intravenous iron, primarily ferric carboxymaltose, has shown clinical benefit in this setting, irrespective of the anemia status. Practical recommendations though are lacking. In this document, we have tried to cover the practical gap and provide useful details for intravenous iron use.Copyright © 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

22 keywords...

hide…